Abstracts Archive - Page 371 of 2607 - ACR Meeting Abstracts

Abstract Number: 1090 • ACR Convergence 2023
Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center
Shelby Gomez¹, Trisha Ludwig¹, Katherine Hartkopf², Sancia Ferguson³, Lori Zemlicka⁴, Mindy Jones⁵ and Christie M. Bartels⁶, ¹UW Health Pharmacy, Madison, WI, ²Pharmacy Society of Wisconsin, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴UW Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: We embedded a clinical pharmacist into our university rheumatology clinics beginning in June 2022 to improve patient experience and reduce provider burden based on…
Abstract Number: 1106 • ACR Convergence 2023
Monosodium Urate and Calcium Pyrophosphate Crystal-induced Inflammation Relies on Cell Volume Regulation and LRRC8/VRAC Channel Activation
Twinu Wilson Chirayath¹, mete kayatekin², Isabelle Rubera³, Nghia Pham⁴, FREDERIC LIOTE⁴, Pascal Richette⁵, Vincent COMPAN⁶, François Rassendren⁷, Christophe Duranton³ and Hang Korng EA⁴, ¹INSERM, Paris, France, ²CNRS-UMR7370, Nice, France, ³CNRS-UMR 7370, Nice, France, ⁴INSERM-BIOSCAR, Paris, France, ⁵Lariboisière Hospital, Paris, France, ⁶CNRS-IGF, Montpellier, France, ⁷CNRS UMR 5203, Montpellier, France
Background/Purpose: Monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals are responsible for interleukin (IL)-1β dependent acute arthritis. The release of mature IL-1β is dependent on…
Abstract Number: 1129 • ACR Convergence 2023
Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study
Saeyun Lee¹, Sujin Kim², Suzanne Segerstrom², Polly Ferguson¹ and Aleksander Lenert³, ¹University of Iowa Carver College of Medicine, Iowa City, IA, ²University of Kentucky, Lexington, KY, ³University of Iowa, Iowa City, IA
Background/Purpose: Autoinflammatory syndromes (AIS), a group of rare rheumatic diseases driven by the innate immune system, remain understudied due to the lack of prospective cohorts.…
Abstract Number: 1125 • ACR Convergence 2023
A Rheumatologic Clinical Profile of the VEXAS Syndrome: Results from a Survey Conducted Among Rheumatologic Units of 126 Hospitals Across Spain
Marta López I Gómez¹, Paula García Escudero², Marta López³, Berta Magallanes López⁴, Meritxell Salles Lizarzaburu⁵, Beatriz Frade Sosa⁶, Elena Riera⁷, Ernesto Trallero Araguás⁸, MARIA ELVIRA DIEZ ALVAREZ⁹, Francisco Javier Toyos Sáenz de Miera¹⁰, Alicia Garcia Dorta¹¹, José Ángel Hernández Beriain¹², Marta Ibáñez Martínez¹³, carolina Merino¹⁴, PALOMA VELA¹⁵, Ana Victoria Orenes Vera¹⁶, Diego Dios Santos¹⁷, Jose Alberto Miranda Filloy¹⁸, Clara García Belando¹⁹, María Rodríguez Laguna²⁰, Ignacio Vázquez²¹, Joaquin Belzunegui²², Judit Font²³, Carlos de Miguel Sánchez²⁴, Zuriñe Ortiz de Zárate Caballero²⁵ and Jaime Calvo Alén²⁶, ¹Hospital Universitario de Araba, Pamplona, Spain, ²Hospital Universitario Araba, Bilbao, Spain, ³Hospital Universitario Arava, Pamplona, Spain, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵C. H. de Manresa - Fundació Althaia, Barcelona, Spain, ⁶Hospital Clínic de Barcelona, Barcelona, Spain, ⁷H. U. Mútua Terrasa, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de León, León, Spain, ¹⁰Hospital Virgen Macarena, Sevilla, Spain, ¹¹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹²Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹³C. A. U. de Salamanca, Salamanca, Spain, ¹⁴Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ¹⁵Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹⁶H. Arnau de Vilanova, Valencia, Spain, ¹⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁸C. H. U. Lucus Augusti, Lugo, Spain, ¹⁹Hospital Los Arcos del Mar Menor, Murcia, Spain, ²⁰H. Clínico San Carlos, Madrid, Spain, ²¹H. U. Dr. Peset, Valencia, Spain, ²²H. C. Alto Deba, Donostia, Spain, ²³Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ²⁴Hospital Universitario de Araba, Hematology, VItoria, Spain, ²⁵Hospital Universitario de Araba, Internal Medicine, Vitoria, Spain, ²⁶Hospital Universitario Araba, Vitoria, Spain
Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…
Abstract Number: 1109 • ACR Convergence 2023
Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis
Blanka Stiburkova¹, Katerina Pavelcova², Jana Masinova¹, Marketa Pavlikova³ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Praha 2, Czech Republic, ³Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
Abstract Number: 1126 • ACR Convergence 2023
Identification of Clinical Phenotypes in Behçet’s Disease Using a Cluster Analysis
Ana Serrano-Combarro¹, Jose Luis Martin-Varillas², Raul Fernandez-Ramon³, Lara Sanchez-Bilbao⁴, Carmen Alvarez Reguera³, ELENA Aurrecoechea⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Hospital de Laredo, Laredo, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵HOSPITAL SIERRALLANA, Cantabria, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behcet's disease (BD) is a variable-vessel vasculitis with a high variability of clinical manifestations. The objective of our study was to identify clinical phenotypes…
Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Roba Ghossan¹, Ouidade Aitisha Tabesh², Fouad Fayad², Pascal Richette³ and Thomas Bardin⁴, ¹COCHIN HOSPITAL, Paris, France, ²Hotel Dieu de France, Beirut, Lebanon, ³Lariboisière Hospital, Paris, France, ⁴Université de Paris Cité, Paris, France
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…
Abstract Number: 1133 • ACR Convergence 2023
Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center
William Rigby¹, Todd Mackenzie², Emily Campbell¹, Joshua Skydel³, Bryan Savage¹, Monica Dimambro² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed…
Abstract Number: 1122 • ACR Convergence 2023
The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy
Cindy Cao¹, Greg Gamble¹, Anne Horne¹, Opetaia Aati¹, Anthony Doyle¹, Jill Drake², Lisa Stamp³ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Te Whatu Ora Waitaha, Christchurch, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: In 2015, the 20-item Tophus Impact Questionnaire (TIQ-20) was developed as a tophus-specific patient reported outcome measure (Aati et al., 2015). Initial analysis of…
Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Brian LaMoreaux¹, Chelsea McKibbon², Katie Obermeyer¹, Lissa Padnick-Silver¹, Gerald Smith², Jiaxuan Wang² and Haridarshan Patel¹, ¹Horizon Therapeutics, Deerfield, IL, ²Cytel Inc., Vancouver, BC, Canada
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…
Abstract Number: 1079 • ACR Convergence 2023
Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements
Tawnie Braaten¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵ and Grant Cannon⁵, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Immune Checkpoint Inhibitor (ICI)-induced myositis (ICI-myositis) is a rare, but potentially fatal complication of ICI therapy.Electronic health record (EHR) databases are essential to accrue…
Abstract Number: 1131 • ACR Convergence 2023
Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort
Choon Guan Chua¹, Weida Chew¹, Jeggrey Kay Wee Kam¹, Hwee-Pin Phua¹, Chengzi Chow¹, Carol Yee-Leng Ng¹, Wei-Yen Lim¹, Ru Sin Lim¹, Jereme Yijin Gan¹, Mung-Ee Loh¹, Tianrong Yeo², David Zhiwei Law¹, Stephrene Seok Wei Chan³, Amanda Francesca Ya-Fang Cheang⁴, Yong-Howe Ho¹ and Charles Kien-Fong Vu¹, ¹Tan Tock Seng Hospital, Singapore, Singapore, ²National Neurology Institute, Singapore, Singapore, ³National University Hospital, Singapore, Singapore, ⁴Woodlands Health Campus, Singapore, Singapore
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition that is heterogenous and can result in organ failure. To understand the disease profile of our local…
Abstract Number: 1113 • ACR Convergence 2023
Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients
Amanuel Kehasse¹, Sayali Dhamne², Michael LaValley³, Jean Liew² and Tuhina Neogi⁴, ¹Boston Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: The management of gout remains poor despite the availability of effective medications and recommendation of a treat-to-target treatment strategy using of urate-lowering therapy (ULT).…
Abstract Number: 1075 • ACR Convergence 2023
Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Lourdes Gonzalez Arreola¹, Carrie Ye², Marie Hudson³, Janet Roberts⁴, Janet Pope⁵, Thomas Appleton⁵, Sabrina Hoa⁶, Aurore Fifi-Mah⁷, Nancy Maltez⁸, Alexandra Saltman⁹, Megan Himmel⁹, Ines Colmegna¹⁰, Alexandra Ladouceur¹¹, Anthony Obrzut¹, Jeremiah Tan¹², David Moon², Tatiana Nevskaya⁵, Emma Schmidt¹³, Lindsay Cho⁴, Nader Toban¹⁴ and Shahin Jamal¹⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Ottawa Hospital, Ottawa, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ¹²Arthritis Research Canada, Vancouver, Canada, Vancouver, BC, Canada, ¹³University of British Columbia, Vancouver, BC, Canada, ¹⁴Centre Hospitalier de l'Université de Montréal, Dollard-des-Ormeaux, QC, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of treatment for many cancers. However, most cancer clinical trials for ICI excluded patients with pre-existing…
Abstract Number: 1093 • ACR Convergence 2023
Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases
Liam Huppke¹, Paul Wratil², Marie Bischof², Stefan Wolfrum¹, Fabian Ullrich¹, Delila Singh¹, Julia Lichtnekert¹, Lea Grümme¹, Christina Gebhardt¹, Klaus Krüger³, Franziska Wiesent⁴, Alla Skapenko¹, Oliver Keppler⁵ and Hendrik Schulze-Koops⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ²Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU Munich, Munich, Germany, ³Praxiszentrum St. Bonifatius, Munich, Germany, ⁴Endokrinologikum München, Munich, Germany, ⁵Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU München, Munich, Germany, ⁶Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany
Background/Purpose: Even though individuals with inflammatory rheumatic diseases (IRDs) were excluded from the SARS-CoV-2 vaccine trails, studies have shown that these individuals at risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].